• Sarepta Therapeutics (SRPT) PDUFA of Eteplirsen for Duchenne Muscular Dystrophy

       (0 reviews)

    Clinical and Regulatory
    Event Type: PDUFA
    Timing: 05/26/2016
    Designation(s): Fast Track, Orphan Drug, Priority Review, Rare Pediatric Disease

    This event is set for a specific date and makes planning easier. However, specific dates may change.
    FDA special designations may increase the likelihood of success and decrease the time to approval.
    Learn More

    Disease and Treatment
    Disease: Other
    Indication: Duchenne Muscular Dystrophy
    Lead Indication?: Yes
    Treatment Name: Eteplirsen

    Likelihood of event success varies depending on disease, treatment and lead indication classification.
    Learn More

    Company Information
    Co. Name: Sarepta Therapeutics
    Stock Symbol: SRPT
    Shares Traded: NASDAQ

    The OTC BB and OTC Markets have less stringent reporting and financial requirements than the NASDAQ and NYSE. This may increase the level of risk for investors. Smaller size may have an influence on likelihood of success.
    Learn More

    Event Status
    Event Outcome: Ongoing
    Event Discussion: Forums
    Event Announcement(s): http://www.businesswire.com/news/home/20160208005533/en/Sarepta-Therapeutics-Receives-Notification-PDUFA-Extension-Eteplirsen
    Partnership: Yes

    Partnerships help smaller biotech companies finance the long approval process. Partnership also provides validation the clinical program may be a worthy investment.
    Learn More

    Detailed Event Description from Company Announcement

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-targeted therapeutics, today announced that the U.S. Food and Drug Administration (FDA) will require additional time to complete its review of the New Drug Application (NDA) for eteplirsen, for the treatment of Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. In a notice received from the FDA, the Prescription Drug User Fee Act (PDUFA) date for eteplirsen has been extended to May 26, 2016.

      Report Event

    User Feedback

    There are no reviews to display.